Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

IL-23 inhibitors

7 evidence topics · 9 sources

Decision aid: IL-23 inhibitors
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Guselkumab“44%”“85–90% chance”
Risankizumab“51%”“Not known at present”
Tildrakizumab“32%”“Not known at present”
Network meta-analyses: anti-IL-23 agents, adverse events, and short-term and long-term PASI 90
Drug survival and switching risk with IL-23 inhibitors compared with other biologics